Bristol-Myers Squibb Advances Immunology Pipeline – Could Sotyktu & Cell Therapies Up The Ante?

Bristol-Myers Squibb reported notable second-quarter performance for 2025, illustrating both encouraging advances and some areas of concern. On the positive side, the company showed strong growth in its key oncology and cardiovascular portfolios, along with significant revenue gains in their newer therapeutic areas. Total company revenues reached approximately $12.3 billion, driven by a 17% increase in sales within the growth portfolio. This boost is primarily attributed to the demand for significant brands such as Opdivo, Breyanzi, Reblozyl, and Camzyos.